Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Arteriovenous Malformations Market Forecast: What Market Value Is Expected By 2030?

The market for arteriovenous malformations (AVMs) has demonstrated robust expansion lately, projected to increase from $3.1 billion in 2025 to $3.33 billion by 2026, reflecting a compound annual growth rate of 7.3%. Historically, this growth has been propelled by advancements in neuroimaging, heightened clinical recognition of AVM conditions, the proliferation of dedicated neurosurgical facilities, the integration of endovascular embolization procedures, and the overall expansion of neurological care services within hospitals.

The market for arteriovenous malformations is projected to experience substantial expansion over the coming years, reaching an estimated $4.37 billion by 2030 with a compound annual growth rate of 7.1%. This anticipated growth trajectory is underpinned by several key factors, including a heightened demand for precise diagnostic tools, increased financial commitments to neurovascular research, a broader acceptance of less invasive treatment modalities, a greater emphasis on tailoring treatment strategies to individual patients, and the growing availability of sophisticated interventional equipment. During this forecast period, significant trends are expected to shape the market landscape, such as the wider integration of cutting-edge neuroimaging diagnostics, a rise in the utilization of endovascular treatments that require minimal invasion, a stronger push towards early and precise diagnosis, the increasing implementation of collaborative, multidisciplinary treatment plans, and more robust methods for monitoring patient recovery after interventions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

#Arteriovenous Malformations Market Demand Drivers Creating New Revenue Opportunities

The expanding preference for less invasive interventions is poised to accelerate the expansion of the arteriovenous malformations market. These less invasive approaches involve surgical or therapeutic actions carried out through subtle incisions or catheter-based methods, aiming to minimize physical trauma, expedite recovery periods, and reduce the likelihood of complications. The heightened demand for such surgeries stems from their capacity to facilitate quicker recuperation, as they require smaller cuts, inflict less damage to the body’s tissues, and shorten the overall healing duration. Consequently, patients can resume their regular routines sooner when contrasted with conventional open surgeries, making this approach a more attractive option for both individuals seeking treatment and medical professionals providing care in the arteriovenous malformations market. Techniques like endovascular embolization, which leverage catheters and image guidance to control aberrant blood flow without resorting to open procedures, exemplify how arteriovenous malformations are amenable to less invasive strategies, leading to diminished risks, shorter recovery times, and improved patient outcomes, as evidenced by a 7% rise in minimally invasive cosmetic procedures in the US during 2023, totaling 25,442,640.

Heightened financial commitments within the biotechnology sector are anticipated to be a significant catalyst for the expansion of the arteriovenous malformations market. Biotechnology, in essence, involves the utilization of biological systems, organisms, or processes to create novel healthcare products and technologies. This surge in biotechnology investment is largely attributable to groundbreaking advancements, particularly in gene editing technologies like CRISPR, which facilitate highly accurate genetic alterations that translate into medical innovations. The field of arteriovenous malformations is intrinsically linked to biotechnology through enhancements in medical imaging capabilities, progress in gene therapy applications, and the development of more delicate, minimally invasive treatment modalities, all contributing to sophisticated solutions such as precisely delivered pharmaceuticals, biocompatible materials for repairing blood vessels, and diagnostic tools augmented by artificial intelligence. Illustrating this trend, the UK’s vibrant life sciences and biotechnology industry attracted substantial investment, securing $2.55 billion in the initial half of 2024, thereby exceeding the $2.32 billion total for the entirety of 2023, underscoring the robust growth driven by escalating biotechnology investments within the arteriovenous malformations market.

Arteriovenous Malformations Market Segment Analysis Highlighting Growth Areas

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Arteriovenous Malformations Market Trends Driving Strategic Industry Expansion

In the arteriovenous malformations market, leading corporations are prioritizing innovation, particularly in the development of liquid embolic system procedural sets, with the aim of simplifying treatment processes and enhancing patient results. Such a procedural set is essentially a fully assembled, sterile package containing all the vital items needed for administering liquid embolic agents to address conditions like arteriovenous malformations (AVMs). A prime illustration of this trend is the introduction in March 2024 by CERENOVUS Inc., a US entity specializing in neurovascular care and part of Johnson and Johnson MedTech, of its TRUFILL n-BCA liquid embolic system procedural set. This recently released set offers two distinct configurations alongside all required accessories, conveniently packaged together in a sterile unit to facilitate the preparation and deployment of the n-BCA liquid embolic system for the treatment of cerebral arteriovenous malformations (AVMs), thereby streamlining the pre-procedural workflow.

Arteriovenous Malformations Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Access The Complete Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Arteriovenous Malformations Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the arteriovenous malformations market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model